Biohaven Pharmaceutical Holding Company Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biohaven Pharmaceutical Holding Company Ltd.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
Gilead's Veklury for the treatment of COVID-19 was a clear commercial standout among new drugs in 2020, but cancer drugs like Seagen's Padcev and Tukysa are poised for long-term potential.
- Controlled Release
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Portage Biotech Inc.
- Portage Glasgow Limited (PGL)
- Biohaven Pharmaceuticals, Inc.
- Kleo Pharmaceuticals Inc.